Member Info for TRENCH123

Hi DeBull, think there is a lot more happening than is evident at the moment, so very possible

This article may be of general interest reference the recent RNS Reach release by PYC

https://www.gavi.org/vaccineswork/could-hantavirus-vaccine-be-horizon

Hi DeBull, I don't recall any reference by PYC to work on pancreatic cancer. Who posted the comment on X ?

With regards to the Personalised dosing software there was the following statement in the interim results issued in February :-

' .... the Company has sought additional data sources to advance the development of its Personalised Dosing Software and supplement the clinical trial

dataset. In January 2026, following the H1 to 31 December 2025 reporting period, the Company entered into a Data Usage Agreement with a leading American university, securing access to a substantial dataset from cancer patients undergoing treatment. The evaluation of this dataset is still at an early stage, and the Company will share more information about this new data source and its effect on development in announcements planned for later in the second half of the financial year.

I wonder if the 'planned announcement' due before 30th June, 2026 will still happen with the subsequent change in BOD. I hope so. This is where retaining Pete Sargent longer term would, in my view, be highly beneficial in keeping such projects and general company momentum on track.

It would appear that Dr Mark Davies (Head of Quantitative Pharmacology and Data Science) has moved on and Dr.Malek Hajjawi (Quantitative Pharmacology Scientist) has joined PYC

I would expect an update on Pete Sargent any day now

I was apprehensive when the BOD changes were announced but have been very satisfied with what I have seen from Mike and Co since. An interesting seniior appointment and a professional approach to promoting and progressing the business

On 27th May Pete Sargent commented that 'Our broader pipeline remains strong and we're excited about a number of additional opportunities that we hope to be able to announce soon". Perhaps not long to wait for further news

Porky/Viera why are you so obsessed with Valirx. There is obviously more to it than meets the eye. I can only assume that you have a vested interest in the placings, otherwise why waste your time and energy. Clearly you are not doing it to help anyone other than yourself. Honest replies only please

Yes , an extremely well-written and balanced article. Appears to omit any reference to the advanced work on the personalised dosing tool which could be the most transformative for the company

Be interesting if the likes of Doc Holliday started to take an interest here on such a low mcap.

Looks like a very successful fundraise

Great to meet the @Physiomics team in Oxford over the last 2 days.

We discussed A.I opportunities consistent with #PYC I.T infrastructure, future proofing the business.

Productive 2 days 💪

Fair point

I am not invested here (and am not intending to) but was struck by the extremely positive comments of by both the Chairman and CEO respectively :-

'ValiRx is building an asset rich business which, we believe is massively undervalued. The current raise is a testament to this."

"We believe the current valuation does not fully reflect the breadth of assets, intellectual property and commercial optionality within the Group, and this fundraising is designed to help unlock several potential near-term catalysts."

Will be money well spent if he is able to accelerate commercialisation of PYC dosing tool. I am looking forward to news of progress on the G-CSF trial which could be a real game-changer here

The eternal pessimist is alive and kicking

I agree Laura. Pete's knowledge of PYC and industry contacts would be invaluable

Investors waiting for announcements from new BOD, but this is not something which can be rushed. Patience required

£13k buy at the end of the day

Must be staying on during transition. Hope so, some continuity very useful

Congratulations to Mike and team. Genuine shareholders are behind your efforts to grow the business